HHS Recovery Act Recipient Reporting Readiness Tool

Step 4. Review and Copy the Grant Awards Data

TAGGS provides some – but not all – of the data needed for the Recipient Report. Recipients are responsible for directly collecting and reporting all required data to FederalReporting.gov. Data that HHS does not currently collect are highlighted in yellow. Do not copy this highlighted information. Please enter the appropriate data for your organization in these required fields. For assistance with entering these data please contact FederalReporting.gov.

You may capture the data HHS does provide by copying data from this screen and pasting it into the reporting format of your choice, such as the Excel spreadsheet template, the XML template, or by logging into the online form. For assistance with copying and pasting these data please email our help desk at Readiness Help

Prime Recipient Report

Award Detail for: HIV-INDUCED 5-LIPOXYGENASE: ROLE IN HIV-RELATED PULMONARY ARTERIAL HYPERTENSION
Recipient Name:EMORY UNIVERSITY
DUNS Number: 066469933
1784 N DECATUR RD,S 530 NDBLDG
ATLANTA, GA 30322-1048

Reporting Information

Award Type*: Grant

Award Number*: 5F31AI084460-02

Final Report*: Recipient responsible for this data

Award Recipient Information

Recipient DUNS Number*: 066469933

Recipient Account Number: Recipient responsible for this data

Recipient Congressional District*: 5

Award Information

Funding Agency Code*: 7529

Awarding Agency Code*:7529

Award Date*: 06-03-2010

Amount of Award*: $ 29,328

Program Source (TAS)*: 750900

CFDA Number*: 93.701

Sub Account Number for Program Source (TAS)*: Recipient responsible for this data

Total Number of Sub Awards to Individuals*: Recipient responsible for this data

Total Amount of Sub Awards to Individuals*: Recipient responsible for this data

Total Number of Payments to Vendors less than $25,000/award*: Recipient responsible for this data

Total Amount of Payments to Vendors less than $25,000/award*: Recipient responsible for this data

Total Number of Sub Awards less than $25,000/award*: Recipient responsible for this data

Total Amount of Sub Awards less than $25,000/award*: Recipient responsible for this data

Award Description* DESCRIPTION (provided by applicant): We have found that HIV-1 transgenic rats and HIV-1-treated co-cultures containing human pulmonary artery endothelial cells (HPAEC) and peripheral blood mononuclear cells (PBMC) demonstrate striking increases in arachidonate 5-lipoxygenase (AL0X5) mRNA expression. AL0X5 is the enzyme that produces leukotrienes (LT) from arachidonic acid. These LT include LTB4 and the potent vasoconstrictors, LTC4, LTD4 and LTE4. We believe HIV-induced increases in AL0X5 expression could yield elevated LT levels and potentially contribute to the progression of PAH, a disorder characterized by pulmonary vasoconstriction and vascular remodeling, by inducing vasoconstriction of the pulmonary vasculature. Previous works suggest that HIV-1 may play a role in PAH pathogenesis through the release of various virus-associated mediators and not through direct vascular contact. One potential mechanism in the etiology of HIV-associated PAH may exist in the effect of HlV-1 secreted proteins, such as Tat, Nef or gp120. Numerous works have described the effect of HIV-1 protein exposure on human endothelial cells showing increased gene and protein expression of various vasoactive molecules. These studies suggest an active link between HIV-1 proteins and the development of disorders affecting the vasculature. Therefore, we hypothesize that the HIV-1 protein(s) may contribute to HIV-PAH development by altering AL0X5 expression and leukotriene production. To test this hypothesis, we will employ cell cultures and a HIV-1 transgenic (Tg) rat model. Human pulmonary artery endothelial cells will be cultured in the presence or absence of HlV-1 proteins for various exposure times. AL0X5 transcription will be assessed by real-fime PCR and nuclear run-on assays. AL0X5 protein expression and leukotriene producfion will be assessed by western blot and ELISA, respectively. We will also investigate the role of AL0X5 in HIV-PAH progression by administering the AL0X5 inhibitor, Zileuton to HlV-1 Tg rats in the presence or absence of hypoxia. Therefore, in this study, we aim to 1) determine the HIV-1 protein(s) that mediate alterations in endothelial AL0X5 expression and activity and 2) assess the role of AL0X5 in HIV-related PAH. These analyses will lead to a better understanding of HIV-PAH and may yield future preventative measures and therapies for HIV-PAH and PAH sufferers. Moreover, these studies may elucidate ALOX5 expression as a potential biomarker of HIV-PAH disease development and severity. PUBLIC HEALTH RELEVANCE: As a fellowship recipient, I aim to participate in publication, proposal and grant-writing workshops. The ability to write clearly and concisely plays a critical role in academia and is an essential tool in becoming a successful scientific investigator. I also plan to participate in a variety of teaching opportunities. As an aspiring college professor, it is incredibly vital to be skilled at conveying information to others in an engaging manner In addition this fellowship will prove especially helpful in the completion of my dissertation and transition to an academic faculty member. The last two years will coincide with the senior segment of my graduate education. At this stage, it will become imperative that I utilize the available mentorships to assist me in obtaining postdoctoral appointments. Following the completion of my doctoral degree, I plan to obtain a postdoctoral position in a prominent laboratory studying pulmonary vascular disease. During this time, I plan to acquire further research training and experience teaching at the collegiate level. Attaining a professoriate position at a minority-serving institution is a long-term goal and personal career objective. It is very important that well-qualified and passionate teachers and professors remain a staple in today's schools and universities. These academic faculty members play a critical role in inspiring our youth to become the next generation of teachers, scientists, and doctors.

Project Information

Project Name or Project/Program Title*: HIV-INDUCED 5-LIPOXYGENASE: ROLE IN HIV-RELATED PULMONARY ARTERIAL HYPERTENSION

Project Status*: Recipient responsible for this data

Total Federal Amount of ARRA Funds Received/Invoiced*: Recipient responsible for this data

Number of Jobs*: Recipient responsible for this data

Description of Jobs Created*: Recipient responsible for this data

Quarterly Activities/Project Description*: Recipient responsible for this data

Activity Code (NAICS or NTEE-NPC)*: Recipient responsible for this data

Total Federal Amount of ARRA Expenditure* (Enter the cumulative total amount of Recovery Funds received that were expended to projects or activities. Refer to the Data Model for details on how to calculate this amount.): Recipient responsible for this data

Total Federal ARRA Infrastructure Expenditure Recipient responsible for this data

Infrastructure Contact Name: Recipient responsible for this data

Infrastructure Contact Email: Recipient responsible for this data

Infrastructure Contact Phone: Recipient responsible for this data

Infrastructure Contact Phone Ext: Recipient responsible for this data

Infrastructure Contact Street Address 1: 1784 N DECATUR RD,S 530 NDBLDG

Infrastructure Contact Street Address 2: Not Available

Infrastructure Contact Street Address 3: Recipient responsible for this data

Infrastructure City: ATLANTA

Infrastructure State: GA

Infrastructure ZIP Code+4: 30322-1048

Infrastructure Purpose and Rationale (If applicable, enter an explanation about how the infrastructure investment will contribute to one or more purposes of the Recovery Act. Refer to the Data Model for details on what to report. 4000 characters or less.): Recipient responsible for this data

Primary Place of Performance

Street Address 1: 1670 CLAIRMONT ROAD, 151-P

Street Address 2: DECATUR

City*: DECATUR

State*: GA

ZIP Code+4*: 300033400

Congressional District*: 4

Country*: US

Recipient Highly Compensated Officers

Prime Recipient Indication of Reporting Applicability*: Recipient responsible for this data

1. Officer Name and Compensation: Recipient responsible for this data
2. Officer Name and Compensation: Recipient responsible for this data
3. Officer Name and Compensation: Recipient responsible for this data
4. Officer Name and Compensation: Recipient responsible for this data
5. Officer Name and Compensation: Recipient responsible for this data

This concludes the current search. To begin a new search, return to the HHS Recovery Act Recipient Reporting Readiness Tool Landing Page.